Agilent Expands Rosetta Alliance, Targets Growth In DNA Microarray Market | GenomeWeb

P

ALO ALTO, Calif.--Agilent Technologies here announced the expansion of its alliance with Rosetta Inpharmatics to include Rosetta’s FlexJet DNA microarray technology. This announcement follows an earlier agreement between the two companies to develop and distribute Rosetta’s gene expression analysis software platform, the Rosetta Resolver Expression Data Analysis System. As a complement to its own inkjet array technology used to develop catalog type arrays, Agilent will further develop, manufacture, and distribute the FlexJet arrays.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.